WO2018014098A1 - Use of pharmaceutical composition for the treatment of skin erythema in periorbital dark circles - Google Patents
Use of pharmaceutical composition for the treatment of skin erythema in periorbital dark circles Download PDFInfo
- Publication number
- WO2018014098A1 WO2018014098A1 PCT/BR2017/050123 BR2017050123W WO2018014098A1 WO 2018014098 A1 WO2018014098 A1 WO 2018014098A1 BR 2017050123 W BR2017050123 W BR 2017050123W WO 2018014098 A1 WO2018014098 A1 WO 2018014098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alpha
- dark circles
- active substance
- erythema
- quinoxalin
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention belongs to to the technological sector of the cosmetic and pharmaceutical industries and refers more specifically to a composition of second use developed for treating a condition specific dermatological disorder consisting of dark circles erythema.
- the origin of dark circles is usually multifactorial.
- the main causes are melanin deposition in the dermis, postinflammatory hyperpigmentation secondary to dermatitis atopic or allergic disease, periorbital edema, localization vascularization of the eyelid skin vascularization, blood circulation stasis and shading due to deepening of the nasojugal sulcus and the sagging skin of the eyelid.
- Violet or darkened appearance of eyelids is characteristic of dark circles and is due to the sum of several factors, including the thin, translucent thickness of the lower eyelid skin allowing transparency of other structures. Other factors consist in the fact that the tissue subcutaneous fat is very thin, there is a vascularization subcutaneous tissue at this location, the regional anatomy favoring venous stasis and localization orbicularis oculi superficial muscle.
- the constitutional type was found in 38.6% of the patients, being characterized by the presence of curved band hyperpigmentation of brownish to black, located on the lower eyelids along the following the shape of the orbital edge, usually involving also the upper eyelids.
- Already dark circles of 12% of patients were diagnosed as secondary to postinflammatory hyperpigmentation, secondary to dermatitis and 11.4% of the patients' dark circles were characterized as secondary to the shading effect caused by nasojugal sulcus and infra-eyelid fat herniation.
- bradykinin antagonist compound selected use in a topical composition of at least one bradykinin antagonist compound selected, treatment process cosmetic and cosmetic, pharmaceutical or dermatological composition ”which describes the use of a bradykinin antagonist for the treatment of sensitive skin, aimed at preventing and / or combating skin irritations, skin diseases, erythema, dysesthetic sensations, among other symptoms.
- the invention also relates to a composition which limits or eliminates the irritating side effects of certain products and in particular of certain dermatological or pharmaceutical cosmetic active agents.
- these topical agents with bradykinin antagonists act on the erythema from inflammation and irritation, not acting on the chronic erythema of dark circles of vascular origin.
- US Patent No. 2016082007 - “Method and therapeutic / cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists ” features a directed composition treatment of skin erythema such as rosacea and other conditions characterized by increased redness of the skin. These conditions exhibit dilation of the blood vessels due to to a vascular cutaneous hyperreactivity.
- the present invention is directed to a novel composition and method for the treatment of skin erythema using agonists [alpha] -1-adrenergics incorporated in cosmetics, pharmacological or dermatological compositions for application
- this composition does not provide for the treatment of chronic erythema of dark circles.
- Newer alternatives consist of cosmetics used to reduce the dermatological condition of dark circles on individuals.
- Patent document BR 11 2015 011021 5 Cosmetic active ingredient, topical composition, and methods for enhancing the activity of heme oxygenase type 1 in human skin and for reducing the appearance of dark circles and fine lines and wrinkles on the skin below and below. around the eye area .
- the invention proposed in the present document provides for the use of an active ingredient extracted from Focus vesiculosus seaweed for the treatment of dark circles.
- the patent in question further provides compositions having such an active ingredient for the treatment of this kind of dermatological condition.
- this invention does not describe improvement of chronic dark circles erythema.
- patent document BR 10 2013 011812 5 - “ Dark circles cream ”, which describes Dark Circles Cream is elaborating, among other substances, with the addition of Avena Eyes with a concentration of 5% and Dermatansulfate with 2%, used for dark circles, promoting regenerative, fibrinolytic, vasodilating and anti-edema action, helping to maintain skin integrity.
- substances with immunostimulating and antioxidant and healing anti-inflammatory action such as BIOSKINUP CONTOUR, were added to the formula.
- BIOSKINUP CONTOUR were added to the formula.
- the drawback of the proposed cream is that the composition has no vasoconstrictor action to produce improvement of the chronic dark circles erythema.
- the present invention aims to propose the use of substances of the group pharmacology of receptor agonists adrenergic agents, whether or not associated with products and / or cosmetic compositions for the treatment of dark circles.
- Topical brimonidine consists of an agonist alpha-2-adrenergic that was initially used to decrease intraocular pressure in patients with glaucoma or ocular hypertension. From subsequent studies related to such substance, there was the development of various medicines that were intended for vasoconstriction blood vessels, since it was detected an important vasoconstrictor characteristic that shows the improvement in conditions that cause erythema on the skin of patients.
- the The present invention relates to novel compositions involving the use of alpha-adrenergic agonists such as brimonidine or another drug in the same pharmacological group as the agonists of alpha-adrenergic receptors to be used for the treatment of dark circles erythema.
- alpha-adrenergic agonists such as brimonidine or another drug in the same pharmacological group as the agonists of alpha-adrenergic receptors to be used for the treatment of dark circles erythema.
- Such a substance is present in different concentrations or compositions may or may not be associated with other compounds.
- the application of topical products containing alpha-adrenergic agonists alone or in combination with other compounds results in significant improvement of skin darkening in lesions of this condition dermatological condition present in the eye region.
- composition in question consists of an active substance in the group alpha-adrenergic receptor agonists, more specifically, brimonidine together with a vehicle q.s.p pharmaceutically acceptable.
- composition object of this report descriptive, comprises the topical use of the active substance brimonidine in concentrations ranging from 0.1% to 0.5%, another drug may also be used, provided that the same belonging to the same agonist group alpha-adrenergic.
- concentration used consists of therapeutic concentrations that guarantee the results of vasoconstriction of blood vessels in the eye region concerning dark circles, being an agent alpha adrenergic.
- the use of composition in the same is applied to the lower eyelids of the patients with dark circles and who appear darkened eye area, a symptom that is more frequent in the medial part of the lower eyelids.
- the topical composition with the active ingredient brimonidine may also be associated with other compounds. These compounds, to which the brimonidine may be associated, should target treatment of other characteristic skin changes related to dark circles such as the hyperpigmentation, sagging or wrinkles. Therefore, the active substance brimonidine may also be associated with depigmenting compounds or even compounds collagen production stimulators.
- FIGs 1 to 6 aim to prove the effectiveness of the application of use of compositions containing the active ingredient brimonidine in patients with skin rash lower eyelids with dark circles.
- Figures 1, 3 and 5 it is possible to observe the images of three patients have chronic dark circles erythema before application of a product containing the agonist alpha-2-adrenergic brimonidine.
- a product containing 0.33% concentration of brimonidine in the skin of the lower eyelids of the individual For example, a product containing 0.33% concentration of brimonidine in the skin of the lower eyelids of the individual.
- Figures 2, 4 and 6 show images of the appearance of the treated region, or that is, the improvement of the erythema of the lower eyelids dark circles, in this case, images were presented about 60 minutes after application of the drug.
- composition proposed in the present invention usually gradually increase in the first 3 hours after after a time interval of 6 to 9 hours. Therefore, morning application of or up to 6 hours before the patient desire the effects of the product. Comparing the two It is evident that the application of the composition in question, for dark circles erythema, results in improved of the drawback present in this condition.
- a set of compounds of the pharmacological group of alpha-adrenergic receptors that can also be used in the treatment of dark circles, since the results obtained are analogous to brimonidine.
- Some Non-limiting examples of such substances include: apraclonidine, clonidine, desglimidodrine, dexmedetomidine, dopamine, ephedrine, epinephrine, epinine (N-methyl dopamine), ethylnorepinephrine, phenylephrine, phenylpropanolamine, guanabenzo, guanfacine, l-dobutamine, Levarterenol, Lofexidine, Mepentermine, metaraminol, methylphenidate, methoxamine, midodrine, mitodrine, mivazerol, moxonidine, naphazoline, norepinephrine, norphenylphrine, oxymetazoline,
- compositions for topical use consisting of in the use of a composition containing a substance of the pharmacological group of receptor agonists adrenergic agents such as brimonidine or another drug of the same pharmacological group, intended for the treatment of dark circles erythema, endowed with novelty, activity inventive, descriptive and demonstrative sufficiency, industrial application and therefore coated with essential requirements for the granting of the pleaded privilege.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention belongs to the technological field of the cosmetic and pharmaceutical industries and relates, more specifically, to a second use composition developed for treating a specific dermatological condition, the skin erythema in periorbital dark circles. The solution described in the present document relates to the use of a composition containing a substance of the pharmacological group of alpha-adrenergic receptor agonists, such as brimonidine or other drugs of the same pharmacological group. This substance is present in the composition in effective therapeutic quantities for treating the vascular component of the erythema which is generally present in the area of the lower eyelids, known under the common name of dark circles under the eyes. Owing to the vascular component of this condition, when the product is applied to the area of the lower eyelids, a significant decrease in the chronic florid or reddish and/or darkened aspect of this area is observed, because of the vasoconstrictive effect of the product. The composition can thus be also associated with other compounds in order to provide alternatives to change the darkened aspect of this area.
Description
De uma maneira geral a presente invenção pertence
ao setor tecnológico das indústrias cosmética e farmacêutica
e se refere, mais especificamente, a uma composição de
segundo uso desenvolvida para o tratamento de uma condição
dermatológica específica que consiste no eritema cutâneo das olheiras.In general the present invention belongs to
to the technological sector of the cosmetic and pharmaceutical industries
and refers more specifically to a composition of
second use developed for treating a condition
specific dermatological disorder consisting of dark circles erythema.
As olheiras constituem um problema muito frequente
e são caracterizadas por alterações de cor da pele da
pálpebra inferior e pela profundidade do sulco nasojugal.
Esta condição pode ser observada em indivíduos de todas as
idades e muitas vezes acaba por prejudicar a autoestima e
vida social das pessoas, pois os indivíduos com esse tipo de
condição dermatológica geralmente são associados a um
aspecto triste, cansado, estressado e envelhecido. Apesar de
ser um problema inestético muito comum, existem poucos
estudos relacionados à sua etiologia, histologia e terapia. Dark circles are a very common problem
and are characterized by changes in skin color of the
lower eyelid and the depth of the nasojugal groove.
This condition can be observed in individuals of all ages.
ages and often ends up harming self esteem and
people's social life, because individuals with this kind of
dermatological condition are usually associated with a
looking sad, tired, stressed and aged. in spite of
be a very common unsightly problem, there are few
studies related to its etiology, histology and therapy.
A origem das olheiras geralmente é multifatorial.
As principais causas são a deposição de melanina na derme, a
hiperpigmentação pós-inflamatória secundária a dermatite
atópica ou alérgica, o edema periorbitário, a localização
superficial da vascularização da pele das pálpebras, a
estase da circulação sanguínea e o sombreamento devido ao
aprofundamento do sulco nasojugal e a flacidez da pele da
pálpebra. The origin of dark circles is usually multifactorial.
The main causes are melanin deposition in the dermis,
postinflammatory hyperpigmentation secondary to dermatitis
atopic or allergic disease, periorbital edema, localization
vascularization of the eyelid skin vascularization,
blood circulation stasis and shading due to
deepening of the nasojugal sulcus and the sagging skin of the
eyelid.
A aparência violácea ou escurecida das pálpebras
inferiores é característica das olheiras e se deve a soma de
vários fatores, incluindo a espessura fina e translúcida da
pele na pálpebra inferior permitindo transparência de outras
estruturas. Outros fatores consistem no fato do tecido
adiposo subcutâneo ser muito fino, haver uma vascularização
subcutânea exuberante nesta localização, a anatomia regional
favorecendo a estase venosa e ainda a localização
superficial do músculo orbicular dos olhos.Violet or darkened appearance of eyelids
is characteristic of dark circles and is due to the sum of
several factors, including the thin, translucent thickness of the
lower eyelid skin allowing transparency of other
structures. Other factors consist in the fact that the tissue
subcutaneous fat is very thin, there is a vascularization
subcutaneous tissue at this location, the regional anatomy
favoring venous stasis and localization
orbicularis oculi superficial muscle.
Um estudo retrospectivo, “
Periorbital
hyperpigmentation in Asians: an epidemiologic study and
a proposed classification”, realizado em Singapura e
publicado na revista médica
Dermatologic Surgery em
2011, avaliou 200 pacientes asiáticos com olheiras e,
através da história clínica e exame clinico, classificou as
olheiras em quatro tipos: vascular; constitucional; causadas
por hiperpigmentação pós-inflamatória; ou por efeito de
sombreamento. As olheiras do tipo vascular foram as mais
frequentes, com 41.8% dos pacientes afetados. O tipo
vascular de olheiras é caracterizado pela presença de
eritema envolvendo predominantemente a porção medial das
pálpebras inferiores. O eritema ocorre devido a presença de
capilares preominentes, telangiectasias ou pela presença de
coloração escurecida das pálpebras inferiores, que se deve
às veias visíveis de cor azulada, as quais se tornam
proeminentes quando a pele desta região é esticada.A retrospective study, “ Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification ”, conducted in Singapore and published in the medical journal Dermatologic Surgery in 2011, evaluated 200 Asian patients with dark circles and, through clinical history and clinical examination, ranked the dark circles under four types: vascular; constitutional; caused by postinflammatory hyperpigmentation; or by shading effect. Vascular dark circles were the most frequent, with 41.8% of affected patients. The vascular type of dark circles is characterized by the presence of erythema predominantly involving the medial portion of the lower eyelids. The erythema occurs due to the presence of predominant capillaries, telangiectasias or the presence of darkening of the lower eyelids, which is due to visible bluish veins, which become prominent when the skin of this region is stretched.
O tipo constitucional foi encontrado em 38.6% dos
pacientes, sendo caracterizado pela presença de
hiperpigmentação em banda curva de coloração amarronzada a
preta, localizada nas pálpebras inferiores ao longo e
seguindo o formato da borda orbitária, geralmente envolvendo
também as pálpebras superiores. Já as olheiras de 12% dos
pacientes foram diagnosticadas como secundárias à
hiperpigmentação pós-inflamatória, secundárias a dermatites
crônicas e 11.4% das olheiras dos pacientes foram
caracterizadas como secundárias ao efeito de sombreamento
causado pelo sulco nasojugal e herniação da gordura infra palpebral.The constitutional type was found in 38.6% of the
patients, being characterized by the presence of
curved band hyperpigmentation of brownish to
black, located on the lower eyelids along the
following the shape of the orbital edge, usually involving
also the upper eyelids. Already dark circles of 12% of
patients were diagnosed as secondary to
postinflammatory hyperpigmentation, secondary to dermatitis
and 11.4% of the patients' dark circles were
characterized as secondary to the shading effect
caused by nasojugal sulcus and infra-eyelid fat herniation.
Portanto, este estudo mostra que o tipo mais comum
de olheiras é o tipo vascular. Tendo isso em vista, é
possível destacar que os tratamentos mais comumente
descritos para a melhora do eritema das olheiras consistem
apenas na luz intensa pulsada, do inglês
Pulsed Dye
Laser, e o laser de CO
2 fracionado, o que
comprova a falta de pesquisas e estudos publicados na
literatura médica relacionados à esta área. Além destes
tratamentos, alguns produtos tópicos têm sido relatados para
melhora da hiperpigmentação, flacidez e rugas das pálpebras
inferiores, como despigmentantes tópicos, tais como
hidroquinona, ácido kójico, ácido azelaico e ácido
retinóico. Mas, até o presente momento, nenhum produto
tópico foi eficaz em melhorar significativamente o eritema
cutâneo das olheiras, sendo este sintoma mais frequentemente
amenizado ou ocultado através do uso de produtos corretivos,
os quais consistem em soluções não definitivas para tal
condição dermatológica.Therefore, this study shows that the most common type of dark circles is the vascular type. In view of this, it can be highlighted that the most commonly described treatments for the improvement of dark circles erythema consist only of the intense pulsed light, the Pulsed Dye Laser , and the fractional CO 2 laser, which proves the lack of research and studies published in the medical literature related to this area. In addition to these treatments, some topical products have been reported to improve hyperpigmentation, sagging and wrinkles of the lower eyelids, such as topical depigmentants such as hydroquinone, kojic acid, azelaic acid and retinoic acid. But, to date, no topical product has been effective in significantly improving the dark circles erythema, and this symptom is most often mitigated or hidden through the use of corrective products, which consist of non-definitive solutions to such dermatological condition.
Para o tratamento de eritemas existem também
algumas alternativas que representam o atual estado da
técnica e que são descritas em documentos de patentes.
Alguns exemplos podem ser observados como no caso da patente
de invenção nº PI 9604031-9 – “
Uso de pelo menos um
composto escolhido de antagonistas de bradiquina, uso em
uma composição tópica de pelo menos um composto
escolhido de antagonistas da bradiquinina, processo de
tratamento cosmético e composição cosmética,
farmacêutica ou dermatológica” a qual descreve o uso
de um antagonista da bradiquinina para o tratamento de pele
sensível, visando a prevenção e/ou combate de irritações de
pele, doenças de pele, eritema, sensações disestésicas,
entre outros sintomas. Além disso a invenção também se
refere a uma composição que limita ou elimina os efeitos
colaterais irritantes de certos produtos e, em particular,
de certos agentes ativos cosméticos dermatológicos ou
farmacêuticos. Entretanto, estes agentes tópicos com
antagonistas da bradiquinina atuam no eritema proveniente de
inflamações e irritações, não atuando no eritema crônico das
olheiras de origem vascular.For the treatment of erythema there are also some alternatives that represent the current state of the art and which are described in patent documents. Some examples may be seen as in the case of PI No. 9604031-9 - " Use of at least one bradykinin antagonist compound selected, use in a topical composition of at least one bradykinin antagonist compound selected, treatment process cosmetic and cosmetic, pharmaceutical or dermatological composition ”which describes the use of a bradykinin antagonist for the treatment of sensitive skin, aimed at preventing and / or combating skin irritations, skin diseases, erythema, dysesthetic sensations, among other symptoms. . Further the invention also relates to a composition which limits or eliminates the irritating side effects of certain products and in particular of certain dermatological or pharmaceutical cosmetic active agents. However, these topical agents with bradykinin antagonists act on the erythema from inflammation and irritation, not acting on the chronic erythema of dark circles of vascular origin.
Outra alternativa é proposta na patente de
invenção nº PI 0104390-0 –
“Método para redução de
inflamação e eritema” que se refere a um método para
melhorar a vermelhidão e inflamação de pele compreendendo
uma aplicação tópica de uma composição contendo uma
quantidade eficaz de um composto selecionado a partir de uma
alcanolamina, tirosina ou mistura destas substâncias, além
de um veículo cosmeticamente aceitável. Esta alternativa
apresenta o mesmo inconveniente da invenção citada acima
sendo que os agentes tópicos com esta composição atuam no
eritema agudo de origem inflamatória, não atuando no eritema
crônico das olheiras de origem vascular.Another alternative is proposed in EP 0104390-0 - "Method for reducing inflammation and erythema " which relates to a method for improving skin redness and inflammation comprising topically applying a composition containing an effective amount of a compound selected from an alkanolamine, tyrosine or mixture thereof, and a cosmetically acceptable carrier. This alternative has the same drawback as the invention cited above, that topical agents of this composition act on acute erythema of inflammatory origin, not acting on chronic erythema of vascular origin.
A patente americana US 61/254,805 – “
Methods of
treating or preventing acute erythema” descreve
métodos para tratamentos para condições da pele que aparecem
“de repente” ou de forma aguda, com composições
compreendendo um receptor agonista alfa adrenérgico,
preferencialmente a brimonidina. Entretanto, esse método
proposto visa o tratamento apenas para eritemas agudos,
preferencialmente da rosácea, e casos em que surgem eritemas
após procedimentos médicos, diferentemente do eritema das
olheiras que tem aparecimento lento e sua evolução é crônica
e progressiva, como está caracterizado no caso das olheiras
do tipo vascular.US 61 / 254,805 - Methods of treating or preventing acute erythema describes methods for treating skin conditions that appear “suddenly” or acutely, with compositions comprising an alpha adrenergic agonist receptor, preferably brimonidine. However, this proposed method aims at treating only acute erythema, preferably rosacea, and cases in which erythema arises after medical procedures, unlike dark circles erythema that has a slow onset and its evolution is chronic and progressive, as it is characterized by dark circles of the vascular type.
A patente americana US 20140329874 – “
Alpha
adrenergic agonists for the treatment of tissue
trauma” revela um método para tratamento de traumas em
tecidos, tais como danos resultantes de radiação, feridas,
hematomas, bolhas, escoriações, erosões e úlceras. O
tratamento consiste na administração tópica de uma
composição compreendendo uma quantidade terapeuticamente
eficaz de pelo menos um agonista alfa-adrenérgico na área
afetada pelo referido trauma. No entanto, a composição
utilizada não prevê o tratamento do eritema crônico de
olheiras. US 20140329874 - " Alpha adrenergic agonists for the treatment of tissue trauma " discloses a method for treating tissue trauma such as radiation damage, wounds, bruises, blisters, abrasions, erosions and ulcers. The treatment consists of topically administering a composition comprising a therapeutically effective amount of at least one alpha-adrenergic agonist in the area affected by said trauma. However, the composition used does not provide for the treatment of chronic dark circles erythema.
Por fim, a patente americana nº US 2016082007 –
“Method and therapeutic/cosmetic topical compositions for
the treatment of rosacea and skin erythema using
a1-adrenoceptor agonists” apresenta uma composição dirigida
ao tratamento de eritema de pele como a rosácea e outras
condições caracterizadas por uma maior vermelhidão da pele.
Estas condições exibem dilatação dos vasos sanguíneos devido
a uma hiper-reatividade cutânea vascular. Em particular, a
presente invenção é dirigida a uma nova composição e método
para o tratamento de eritema da pele usando agonistas
[alfa]-1-adrenérgicos incorporados em cosméticos,
composições farmacológicas ou dermatológicas para aplicação
tópica, porém esta composição não prevê o tratamento do
eritema crônico de olheiras.Finally, US Patent No. 2016082007 -
“Method and therapeutic / cosmetic topical compositions for
the treatment of rosacea and skin erythema using
a1-adrenoceptor agonists ”features a directed composition
treatment of skin erythema such as rosacea and other
conditions characterized by increased redness of the skin.
These conditions exhibit dilation of the blood vessels due to
to a vascular cutaneous hyperreactivity. In particular, the
present invention is directed to a novel composition and method
for the treatment of skin erythema using agonists
[alpha] -1-adrenergics incorporated in cosmetics,
pharmacological or dermatological compositions for application
However, this composition does not provide for the treatment of
chronic erythema of dark circles.
Alternativas mais recentes consistem em cosméticos
utilizados para redução da condição dermatológica de
aparecimento de olheiras em indivíduos. O documento de
patente BR 11 2015 011021 5 – “
Princípio ativo cosmético,
composição tópica, e, métodos para aumentar a atividade
da heme oxigenase tipo 1 na pele humana e para reduzir o
aparecimento de olheiras e de linhas finas e rugas na
pele abaixo e em torno da área dos olhos”. A
invenção proposta no documento em questão prevê o uso de um
ingrediente ativo extraídos a partir de algas marinhas
Focus vesiculosus para o tratamento de olheiras.
A patente em questão prevê ainda composições dotadas de tal
ingrediente ativo para o tratamento desse gênero de condição
dermatológica. Porém esta invenção não descreve melhora do
eritema crônico de olheiras.Newer alternatives consist of cosmetics used to reduce the dermatological condition of dark circles on individuals. Patent document BR 11 2015 011021 5 - " Cosmetic active ingredient, topical composition, and methods for enhancing the activity of heme oxygenase type 1 in human skin and for reducing the appearance of dark circles and fine lines and wrinkles on the skin below and below. around the eye area . ” The invention proposed in the present document provides for the use of an active ingredient extracted from Focus vesiculosus seaweed for the treatment of dark circles. The patent in question further provides compositions having such an active ingredient for the treatment of this kind of dermatological condition. However this invention does not describe improvement of chronic dark circles erythema.
Outra composição que pode ser aplicada em
olheiras, mas que não objetiva a melhora do eritema crônico
é apresentada no documento de patente BR 10 2013 025584 0 –
“
Creme facial antirugas e olheiras a partir de
quitosana, glicosil-hesperidina e extrato de spilanthes
acmella”. O documento em questão descreve um novo
cosmecêutico com a incorporaçáo de 3 ingredientes ativos:
glicosil-hesperidina, extrato da planta Spilanthes acmella e
quitosana. Este novo cosmético funcional é eficiente na
remoção de rugas, rugas de expressão e olheiras pelo
sinergismo dos 3 constituintes presentes. Another composition that can be applied to dark circles, but which does not aim to improve chronic erythema is presented in patent document BR 10 2013 025584 0 - “ Anti-wrinkle and dark circles facial cream from chitosan, glycosyl hesperidine and spilanthes acmella extract ” . The document in question describes a new cosmeceutical with the incorporation of 3 active ingredients: glycosyl-hesperidine, Spilanthes acmella plant extract and chitosan. This new functional cosmetic is effective in removing wrinkles, expression wrinkles and dark circles by synergism of the 3 constituents present.
Por fim, o documento de patente BR 10 2013 011812
5 – “
Creme para olheiras”, o qual descreve Creme para
Olheiras é elaborando, dentre outras substâncias, com o
acréscimo de Avena Eyes com uma concentração de 5% e
Dermatansulfato com 2%, utilizados para olheiras, promovendo
ação regenerativa, fibrinolítica, vasodilatadora e
anti-edema auxiliando na manutenção da integridade cutânea.
Com o objetivo de reestruturar e despigmentar os tecidos
conectivos frágeis do contorno dos olhos, foram
acrescentadas na fórmula substâncias com ação
anti-inflamatória imunoestimulante e antioxidante e
cicatrizante, como BIOSKINUP CONTOUR. O inconveniente do
creme proposto consiste no fato de que a composição não
apresenta ação vasoconstritora para produzir melhora do
eritema crônico das olheiras.Finally, patent document BR 10 2013 011812 5 - “ Dark circles cream ”, which describes Dark Circles Cream is elaborating, among other substances, with the addition of Avena Eyes with a concentration of 5% and Dermatansulfate with 2%, used for dark circles, promoting regenerative, fibrinolytic, vasodilating and anti-edema action, helping to maintain skin integrity. In order to restructure and depigment fragile connective tissues around the eye, substances with immunostimulating and antioxidant and healing anti-inflammatory action, such as BIOSKINUP CONTOUR, were added to the formula. The drawback of the proposed cream is that the composition has no vasoconstrictor action to produce improvement of the chronic dark circles erythema.
Apesar de existirem alternativas de tratamentos
e/ou amenização do eritema das olheiras através de
procedimentos, como aplicação de lasers e luzes,
estes podem agravar o escurecimento da pele por
estimular a pigmentação. Além disso, salienta-se que algumas
das alternativas que envolvem composições cosméticas
apresentadas acima não são destinadas diretamente ao
tratamento do eritema crônico das olheiras, de origem
vascular. Com base no conhecimento dos
cosméticos/medicamentos atualmente destinados ao tratamento
das condições dermatológicas de olheiras, pode-se constatar
que não existem, até o presente momento, tratamentos tópicos
comprovadamente efetivos para a melhora do eritema cutâneo
crônico das olheiras, sendo que os agentes despigmentantes
tópicos tem se mostrado pouco efetivos no tratamento da
hiperpigmentação destas regiões. Nesse sentido, existe uma
lacuna na área de medicamentos e composições que sejam
eficazes para o tratamento do eritema das olheiras,
particularmente do componente vascular desta condição.Although there are alternative treatments and / or mitigation of dark circles erythema through procedures such as lasers and lights,
These can aggravate the darkening of the skin by stimulating pigmentation. Furthermore, it is noted that some of the alternatives involving cosmetic compositions presented above are not intended directly for the treatment of chronic dark circles erythema of vascular origin. Based on the knowledge of cosmetics / drugs currently destined to the treatment of dark circles dermatological conditions, it can be seen that, to date, there are no proven effective topical treatments for the improvement of chronic dark circles erythema, and depigmenting agents Topical studies have been shown to be ineffective in treating hyperpigmentation of these regions. Accordingly, there is a gap in the field of medicaments and compositions which are effective for treating dark circles erythema, particularly the vascular component of this condition.
A fim de propor o uso de uma substância que seja
eficaz para o tratamento do eritema das olheiras, é proposto
o uso de um composto que visa particularmente atender ao
componente vascular desta condição dermatológica. Assim, a
presente invenção visa propor o uso de substâncias do grupo
farmacológico dos agonistas dos receptores
alfa-adrenérgicos, associado ou não à produtos e/ou
composições cosméticas para o tratamento de olheiras.In order to propose the use of a substance that is
effective for the treatment of dark circles erythema, it is proposed
the use of a compound that is particularly intended to meet the
vascular component of this dermatological condition. So the
The present invention aims to propose the use of substances of the group
pharmacology of receptor agonists
adrenergic agents, whether or not associated with products and / or
cosmetic compositions for the treatment of dark circles.
A brimonidina tópica consiste em um agonista
alfa-2-adrenérgico que foi inicialmente utilizada para
diminuir a pressão intraocular em pacientes com glaucoma ou
hipertensão ocular. A partir de estudos subsequentes
relacionados a tal substância, houve o desenvolvimento de
diversos medicamentos que foram destinados à vasoconstrição
cutânea direta dos vasos sanguíneos, visto que foi detectada
uma importante característica vasoconstritora que evidencia
a melhora nas condições que causam eritema na pele de pacientes.Topical brimonidine consists of an agonist
alpha-2-adrenergic that was initially used to
decrease intraocular pressure in patients with glaucoma or
ocular hypertension. From subsequent studies
related to such substance, there was the development of
various medicines that were intended for vasoconstriction
blood vessels, since it was detected
an important vasoconstrictor characteristic that shows
the improvement in conditions that cause erythema on the skin of patients.
Uma vez que a brimonidina apresenta tais
características é importante o desenvolvimento de
composições que contenham este ativo, mostrando-se uma
alternativa eficaz para ser utilizada na atuação sobre o
componente vascular das olheiras. Tendo isso em vista, a
presente invenção refere-se a novas composições que envolvem
o uso de agonistas alfa-adrenérgico, como a brimonidina ou
outra droga do mesmo grupo farmacológico dos agonistas dos
receptores alfa-adrenérgicos, a ser utilizada para o
tratamento do eritema das olheiras. Tal substância está
presente em diferentes concentrações ou composições
farmacêuticas, podendo ou não ser associada a outros
compostos. A aplicação de produtos tópicos contendo
agonistas alfa-adrenérgicosisoladamente ou em associação com
outros compostos resulta em melhora significativa do
escurecimento da pele nas lesões desta condição
dermatológica presente na região dos olhos.Since brimonidine presents such
characteristics is important the development of
compositions containing this active, showing a
effective alternative to be used in acting on the
vascular component of dark circles. In view of this, the
The present invention relates to novel compositions involving
the use of alpha-adrenergic agonists such as brimonidine or
another drug in the same pharmacological group as the agonists of
alpha-adrenergic receptors to be used for the
treatment of dark circles erythema. Such a substance is
present in different concentrations or compositions
may or may not be associated with other
compounds. The application of topical products containing
alpha-adrenergic agonists alone or in combination with
other compounds results in significant improvement of
skin darkening in lesions of this condition
dermatological condition present in the eye region.
A fim de trazer imagens que ilustrem a ação do uso
da composição proposta no presente pedido de patente de
invenção e a fim de que a solução seja plenamente
compreendida e levada à prática por qualquer técnico deste
setor tecnológico, a mesma será descrita de forma clara,
concisa e suficiente, tendo como base as fotografias anexas,
que a ilustram e subsidiam abaixo listados:In order to bring images that illustrate the action of using
composition proposed in this patent application
invention and in order for the solution to be fully
understood and carried out by any technician of this
technological sector, it will be clearly described,
concise and sufficient, based on the attached photographs,
that illustrate and subsidize it listed below:
Na presente invenção é proposto o uso de uma
composição farmacêutica com eficácia no tratamento do
eritema das pálpebras de pacientes que possuem a
condição dermatológica de olheiras. A composição em
questão é constituída de uma substância ativa do grupo
de agonistas do receptores alfa-adrenérgicos, mais
especificamente, a brimonidina juntamente com um veículo
q.s.p farmaceuticamente aceitável. In the present invention it is proposed to use a
pharmaceutical composition effectively in the treatment of
erythema of the eyelids of patients who have the
dermatological condition of dark circles. The composition in
question consists of an active substance in the group
alpha-adrenergic receptor agonists, more
specifically, brimonidine together with a vehicle
q.s.p pharmaceutically acceptable.
A composição, objeto deste relatório
descritivo, compreende o uso tópico da substância ativa
brimonidina em concentrações que variam de 0,1% a 0,5%,
podendo também ser utilizada outra droga, desde que a
mesma pertença ao mesmo grupo agonistas
alfa-adrenérgicos. A concentração utilizada consiste em
concentrações terapêuticas que garantem os resultados de
vasoconstrição dos vasos sanguíneos da região dos olhos
referentes às olheiras, por ser um agente
alfa-adrenérgico. Quanto ao uso da composição em
questão, a mesma é aplicada nas pálpebras inferiores dos
pacientes com olheiras e que apresentam aspecto
escurecido da região dos olhos, sintoma que é mais
frequente na parte medial das pálpebras inferiores. The composition, object of this report
descriptive, comprises the topical use of the active substance
brimonidine in concentrations ranging from 0.1% to 0.5%,
another drug may also be used, provided that the
same belonging to the same agonist group
alpha-adrenergic. The concentration used consists of
therapeutic concentrations that guarantee the results of
vasoconstriction of blood vessels in the eye region
concerning dark circles, being an agent
alpha adrenergic. As for the use of composition in
the same is applied to the lower eyelids of the
patients with dark circles and who appear
darkened eye area, a symptom that is more
frequent in the medial part of the lower eyelids.
Além disso, a composição tópica com o
princípio ativo brimonidina também pode ser associada a
outros compostos. Esses compostos, aos quais a
brimonidina pode ser associada, devem visar o tratamento
de outras alterações cutâneas características
relacionadas às olheiras como, por exemplo, a
hiperpigmentação, flacidez ou rugas. Portanto, a
substância ativa brimonidina também pode ser associada a
compostos despigmentantes ou mesmo compostos
estimuladores de produção de colágeno.In addition, the topical composition with the
active ingredient brimonidine may also be associated with
other compounds. These compounds, to which the
brimonidine may be associated, should target treatment
of other characteristic skin changes
related to dark circles such as the
hyperpigmentation, sagging or wrinkles. Therefore, the
active substance brimonidine may also be associated with
depigmenting compounds or even compounds
collagen production stimulators.
As imagens apresentadas nas Figuras 1 a 6
objetivam comprovar a eficácia da aplicação de segundo
uso de composições contendo o princípio ativo
brimonidina em pacientes que apresentem eritema cutâneo
de pálpebras inferiores, com olheiras. Nas Figuras 1, 3
e 5 é possível observar a imagens de três pacientes que
apresentam eritema crônico nas olheiras, antes da
aplicação de um produto contendo o agonista
alfa-2-adrenérgico brimonidina. Neste caso,
exemplificativamente foi utilizado um produto contendo
uma concentração de 0.33% de brimonidina na pele das
pálpebras inferiores do indivíduo. Já as Figuras 2, 4 e
6 apresentam imagens do aspecto da região tratada, ou
seja, da melhora do eritema das pálpebras inferiores das
olheiras, no caso, foram apresentadas imagens cerca de
60 minutos após a aplicação do medicamento.The images shown in Figures 1 to 6
aim to prove the effectiveness of the application of
use of compositions containing the active ingredient
brimonidine in patients with skin rash
lower eyelids with dark circles. In Figures 1, 3
and 5 it is possible to observe the images of three patients
have chronic dark circles erythema before
application of a product containing the agonist
alpha-2-adrenergic brimonidine. In this case,
For example, a product containing
0.33% concentration of brimonidine in the skin of the
lower eyelids of the individual. Figures 2, 4 and
6 show images of the appearance of the treated region, or
that is, the improvement of the erythema of the lower eyelids
dark circles, in this case, images were presented about
60 minutes after application of the drug.
Vale ressaltar que os efeitos da composição
farmacêutica proposta no presente invento costumam
aumentar gradativamente nas 3 primeiras horas após a
aplicação, e diminuem após um intervalo de tempo de 6 a
9 horas. Por isso recomenda-se a aplicação matinal do
produto ou até um período de 6 horas antes de o paciente
desejar os efeitos do produto. Comparando-se as duas
imagens fica evidente que a aplicação da composição em
questão, para o eritema das olheiras, resulta em melhora
do inconveniente presente nesta condição. It is noteworthy that the effects of composition
proposed in the present invention usually
gradually increase in the first 3 hours after
after a time interval of 6 to
9 hours. Therefore, morning application of
or up to 6 hours before the patient
desire the effects of the product. Comparing the two
It is evident that the application of the composition in
question, for dark circles erythema, results in improved
of the drawback present in this condition.
Dito isto, é apresentado um conjunto de
compostos do grupo farmacológico dos agonistas dos
receptores alfa-adrenérgicos que também podem ser
utilizados no tratamento de olheiras, visto que os
resultados obtidos são análogos à brimonidina. Alguns
exemplos não limitativos de tais substâncias incluem:
apraclonidina, clonidina, desglimidodrina,
dexmedetomidina, dopamina, efedrina, epinefrina, epinina
(N-metil-dopamina), etilnorepinefrina, fenilefrina,
fenilpropanolamina, guanabenzo, guanfacina,
l-dobutamina, levarterenol, lofexidina, mefentermina,
metaraminol, metilfenidato, metoxamina, midodrina,
mitodrina, mivazerol, moxonidina, nafazolina,
norepinefrina, norfenilefrina, oximetazolina,
pemolinapropilexedrina, propilexedrina, tetrizolina,
tizanidina, xilometazolina, α-metildopa, α-
metilnorepinefrina,
(4,5-dihidro-1H-imidazol-2-il)-(8-metil-quinoxalin-6-il)-amina,
(4,5-dihidro-1H-imidazol-2-il)-quinoxalin-5-il-amina,
(5-bromo-2-metoxi-quinoxalin-
6-il)-(4,5-dihidro-1H-imidazol-2-il)-amina,
(5-bromo-3-metil-quinoxalin-6-il)-(4,5-
dihidro-1H-imidazol-2-il)-amina,
(8-bromo-quinoxalin-5-il)-(4,5-dihidro-1H-imidazol-
2-il)-amina, (8-bromo-quinoxalin-6-il)-(4,5-dihidro-1H-
imidazol-2-il)-amina. That said, a set of
compounds of the pharmacological group of
alpha-adrenergic receptors that can also be
used in the treatment of dark circles, since the
results obtained are analogous to brimonidine. Some
Non-limiting examples of such substances include:
apraclonidine, clonidine, desglimidodrine,
dexmedetomidine, dopamine, ephedrine, epinephrine, epinine
(N-methyl dopamine), ethylnorepinephrine, phenylephrine,
phenylpropanolamine, guanabenzo, guanfacine,
l-dobutamine, Levarterenol, Lofexidine, Mepentermine,
metaraminol, methylphenidate, methoxamine, midodrine,
mitodrine, mivazerol, moxonidine, naphazoline,
norepinephrine, norphenylphrine, oxymetazoline,
pemolinepropylexedrine, propylexedrine, tetrizoline,
tizanidine, xylometazoline, α-methyldopa, α-
methylnorepinephrine,
(4,5-dihydro-1H-imidazol-2-yl) - (8-methyl-quinoxalin-6-yl) -amine,
(4,5-dihydro-1H-imidazol-2-yl) -quinoxalin-5-yl-amine,
(5-bromo-2-methoxy-quinoxalin-2-one
6-yl) - (4,5-dihydro-1H-imidazol-2-yl) -amine,
(5-bromo-3-methyl-quinoxalin-6-yl) - (4,5-
dihydro-1H-imidazol-2-yl) -amine,
(8-bromo-quinoxalin-5-yl) - (4,5-dihydro-1H-imidazol-2-yl)
2-yl) -amine, (8-bromo-quinoxalin-6-yl) - (4,5-dihydro-1 H-
imidazol-2-yl) -amine.
Tratou-se no presente relatório descritivo de
composições dermatológicas para uso tópico que consistem
no uso de uma composição contendo uma substância do
grupo farmacológico dos agonistas dos receptores
alfa-adrenérgicos, como a brimonidina ou outra droga do
mesmo grupo farmacológico, destinada ao tratamento do
eritema das olheiras, dotado de novidade, atividade
inventiva, suficiência descritiva e demonstrativa,
aplicação industrial e, consequentemente, revestido de
todos os requisitos essenciais para a concessão do
privilégio pleiteado. This was a descriptive report on
dermatological compositions for topical use consisting of
in the use of a composition containing a substance of the
pharmacological group of receptor agonists
adrenergic agents such as brimonidine or another drug of the
same pharmacological group, intended for the treatment of
dark circles erythema, endowed with novelty, activity
inventive, descriptive and demonstrative sufficiency,
industrial application and therefore coated with
essential requirements for the granting of the
pleaded privilege.
Claims (7)
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS caracterizado por ser aplicado na preparação de uma composição de um medicamento com eficácia no tratamento da condição dermatológica denominada olheiras. USE OF AN ACTIVE SUBSTANCE FROM THE ALPHA ADRENERGIC RECEPTOR AGONIST GROUP characterized in that it is applied in the preparation of a composition of a medicament effective in treating the dermatological condition called dark circles.
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com a reivindicação 1, e ainda caracterizado pelo fato de substâncias ativas do grupo de agonistas dos receptores alfa-adrenérgicos incluírem: apraclonidina, brimonidina, clonidina, desglimidodrina, dexmedetomidina, dopamina, efedrina, epinefrina, epinina (N-metil-dopamina), etilnorepinefrina, fenilefrina, fenilpropanolamina, guanabenzo, guanfacina, l-dobutamina, levarterenol, lofexidina, mefentermina, metaraminol, metilfenidato, metoxamina, midodrina, mitodrina, mivazerol, moxonidina, nafazolina, norepinefrina, norfenilefrina, oximetazolina, pemolinapropilexedrina, propilexedrina, tetrizolina, tizanidina, xilometazolina, α-metildopa, α- metilnorepinefrina, (4,5-dihidro-1H-imidazol-2-il)-(8-metil-quinoxalin-6-il)-amina, (4,5-dihidro-1H-imidazol-2-il)-quinoxalin-5-il-amina, (5-bromo-2-metoxi-quinoxalin- 6-il)-(4,5-dihidro-1H-imidazol-2-il)-amina, (5-bromo-3-metil-quinoxalin-6-il)-(4,5- dihidro-1H-imidazol-2-il)-amina, (8-bromo-quinoxalin-5-il)-(4,5-dihidro-1H-imidazol- 2-il)-amina, (8-bromo-quinoxalin-6-il)-(4,5-dihidro-1H- imidazol-2-il)-amina. USE OF AN ACTIVE SUBSTANCE OF THE ALPHA-ADRENERGIC RECEPTOR AGONIST GROUP according to claim 1, further characterized by the fact that active substances in the alpha-adrenergic receptor agonist group include: apraclonidine, brimonidine, clonidine, deglimidodrine, dexmedetidine, dexmedetidine dopamine, ephedrine, epinephrine, epinine (N-methyl-dopamine), ethylnorepinephrine, phenylephrine, phenylpropanolamine, guanabenzo, guanfacine, l-dobutamine, levarenenol, lofexidine, mephentermine, metaraminol, methylphenidine, metoxoline, modiazoline, modiazoline, modiazoline , norepinephrine, norphenylphrine, oxymetazoline, pemolinepropylexedrine, propylexedrine, tetrizoline, tizanidine, xylometazoline, α-methyldopa, α-methylnorepinephrine, (4,5-dihydro-1H-imidazol-2-yl) - (8-methyl-quinoxalin-6- (5-bromo-2-methoxy-quinoxalin-6-yl) - (4,5-yl) -amine, (4,5-dihydro-1H-imidazol-2-yl) -quinoxalin-5-yl-amine dihydro-1H-imidazol-2-yl) -amine, (5-bromo-3-methyl-quinoxalin-6-yl) - (4,5- dihydro-1H-imidazol-2-yl) -amine, (8-bromo-quinoxalin-5-yl) - (4,5-dihydro-1H-imidazol-2-yl) -amine, (8-bromo-quinoxalin-5-yl) 6-yl) - (4,5-dihydro-1H-imidazol-2-yl) -amine.
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com a reivindicação 1 e, ainda, caracterizado pela substância ativa do grupo de agonistas dos receptores alfa-adrenérgicos consistir preferencialmente na BRIMONIDINA. Use of an active substance of the ALPHA-ADRENERGIC RECEPTOR AGONIST GROUP according to claim 1 and further characterized in that the active substance of the alpha-adrenergic receptor agonist group consists preferably of BRIMONIDINE .
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com as reivindicações 1 e 2, e ainda caracterizada pela substância ativa ser associada a compostos despigmentantes de clareamento da pele das olheiras. Use of an active substance of the ALPHA-ADRENERGIC RECEPTOR AGONIST GROUP according to claims 1 and 2, further characterized in that the active substance is associated with dark-skinned depigmenting dark circles compounds.
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com as reivindicações 1 e 2, e ainda caracterizada pela substância ativa ser associada a cosméticos corretivos da região das olheiras. Use of an active substance in the Alpha-adrenergic receptor group of agonists according to claims 1 and 2, further characterized in that the active substance is associated with corrective cosmetics of the dark circles region.
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com as reivindicações 1, 2 e 3, e ainda caracterizada por compreender concentrações terapêuticas que variam de 0,10% a 0,50% da substância ativa BRIMONIDINA. USE OF A SUBSTANCE ACTIVE RECEPTOR AGONISTS group of alpha-adrenergic according to claims 1, 2 and 3, further comprising therapeutic concentrations ranging from 0.10% to 0.50% brimonidine of the active substance.
- USO DE UMA SUBSTÂNCIA ATIVA DO GRUPO DE AGONISTAS DOS RECEPTORES ALFA-ADRENÉRGICOS de acordo com as reivindicações 1, 3 e 6, e ainda caracterizada pela substância ativa BRIMONIDINA estar presente em concentração terapêutica de 0,33%. USE OF AN ACTIVE SUBSTANCE OF THE ALPHA-ADRENGER RECEPTOR AGONIST GROUP according to claims 1, 3 and 6, further characterized by Brimonidine active substance is present in therapeutic concentration of 0.33%.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRBR102016016722-1 | 2016-07-19 | ||
| BR102016016722-1A BR102016016722A2 (en) | 2016-07-19 | 2016-07-19 | USE OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CUTANEOUS EYE TREATMENT |
| BR132017006993-0A BR132017006993E2 (en) | 2017-04-05 | 2017-04-05 | use of pharmaceutical composition for the treatment of dark circles erythema |
| BRBR132017006993-0 | 2017-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018014098A1 true WO2018014098A1 (en) | 2018-01-25 |
Family
ID=60991704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2017/050123 WO2018014098A1 (en) | 2016-07-19 | 2017-05-19 | Use of pharmaceutical composition for the treatment of skin erythema in periorbital dark circles |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018014098A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016068975A1 (en) * | 2014-10-31 | 2016-05-06 | Avon Products, Inc. | Topical compositions and methods of use thereof |
-
2017
- 2017-05-19 WO PCT/BR2017/050123 patent/WO2018014098A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016068975A1 (en) * | 2014-10-31 | 2016-05-06 | Avon Products, Inc. | Topical compositions and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| J. JAVIER SERVAT ET AL.: "Effects of Common Topical Antiglaucoma Medications on the Ocular Surface", EYELIDS AND PERIORBITAL TISSUE, DRUGS AGING, vol. 28, no. 4, 2011, pages 267 - 282 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Del Rosso | Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea | |
| CA2703109C (en) | Compositions and methods for treating purpura | |
| RU2530604C2 (en) | Injected combination of agonists of adrenergic receptors with fillers for reduction of skin responses to injection | |
| US10632181B2 (en) | Composition, containing RGD motif-containing peptide or fragment thereof, for treating burns and glaucoma, alleviating skin wrinkles, and promoting hair growth | |
| EP2494954B1 (en) | Ophthalmic composition based on lactobionic acid useful for reducing corneal edema and inflammation | |
| US20140302185A1 (en) | Composition for the treatment of skin lesions | |
| BHATTACHARJEE et al. | Understanding the drug delivery through nails: a comprehensive review | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| WO2018014098A1 (en) | Use of pharmaceutical composition for the treatment of skin erythema in periorbital dark circles | |
| KR20210093748A (en) | Neurotoxin for use in minimizing scarring | |
| KR102221499B1 (en) | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring | |
| BR102016016722A2 (en) | USE OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CUTANEOUS EYE TREATMENT | |
| JPS58162512A (en) | Hair growing agent for premature baldness and circular loss of hair | |
| ITMI20132157A1 (en) | CORTEXOLONE 17ALFA-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. 17ALFA CORTEXOLONE-PROPIONED FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. | |
| EP1397124B1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
| RU2810361C1 (en) | Method of treating ophthalmic rosacea by points | |
| RU2814362C1 (en) | Method of treating rosacea with solid persistent oedema by points | |
| RU2811255C1 (en) | Method of treating rosacea conglobate by points | |
| WO2018000067A1 (en) | Use of an active substance in the treatment of telangiectatic melasma | |
| WO2017161432A1 (en) | Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas | |
| WO2024124206A1 (en) | Topical compositions for treating and preventing hair loss and hair graying | |
| KR20040043596A (en) | Anti-keratin composition comprising cellulose as a effective component | |
| BR102016015213B1 (en) | use of an active substance in the treatment of telangiectasic melasma | |
| KR20040024213A (en) | Non-woven fabric pack impregnated with crude saponin of red ginseng for the improvement of acne | |
| Petese et al. | Enhancement of Eyelash growth using bimatoprost. A clinical trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17830126 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17830126 Country of ref document: EP Kind code of ref document: A1 |